Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.

Wei SangMing ShiJingjing YangJiang CaoLinyan XuDongmei YanMeixue YaoHui LiuWeidong LiBing ZhangKemeng SunXuguang SongCai SunJun JiaoYuanyuan QinTingting SangYuanyuan MaMei WuXiang GaoHai ChengZhiling YanDepeng LiHaiying SunFeng ZhuYing WangLingyu ZengZhenyu LiJunnian ZhengKailin Xu

Published in: Cancer medicine (2020)

Coadministration of anti-CD19 and CD20 CAR-T cells therapy for DLBCL is feasible with manageable toxicity. Cytokine markers are related to toxicity and SUVmax could predict efficacy. This trial was registered at www.clinicaltrials.gov as NCT03207178.

Keyphrases

diffuse large b cell lymphoma
epstein barr virus
nk cells
oxidative stress
acute myeloid leukemia
acute lymphoblastic leukemia
randomized controlled trial
study protocol
open label
phase ii
oxide nanoparticles